Investor
GILEAD SCIENCES, INC.
CIK 0000882095 · filed 2026-02-12 · SEC filing
13F book
$1.94B
Positions
6
Largest name
38.7%
Arcus Biosciences, Inc. · RCUS
Est. mark
—
Need a prior quarter to estimate
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Arcus Biosciences, Inc. | RCUS | 31.4M | $748.9M | 38.7% | — | Held |
| Galapagos Nv | — | 16.7M | $550.6M | 28.4% | — | Held |
| Arcellx Inc | — | 6.72M | $438.2M | 22.6% | — | Held |
| Assembly Biosciences, Inc. | ASMB | 4.51M | $153.2M | 7.9% | — | Held |
| Kyverna Therapeutics, Inc. | KYTX | 4.13M | $38.8M | 2.0% | — | Held |
| Xilio Therapeutics, Inc. | XLO | 9.11M | $5.83M | 0.3% | — | Held |
Positions as of Q4 2025. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.